WANG Jiguang, LIN Jinxiu, CHEN Luyuan, ZHU Zhiming, ZHANG Yuqing, MOU Jianjun, LIU Jing, CHEN Xiaoping, JIANG Yinong, XIE Liangdi, XIE Jianhong, XUE Hao, ZHANG Haifeng, CHEN Xin, JIA Nan, XU Jianzhong, XU Tingyan, CHENG Wenli. Chinese experts consensus on the use of α-blockers in antihypertensive therapy[J]. Chinese Journal of Hypertension, 2022, 30(5): 409-416. DOI: 10.16439/j.issn.1673-7245.2022.05.003
Citation: WANG Jiguang, LIN Jinxiu, CHEN Luyuan, ZHU Zhiming, ZHANG Yuqing, MOU Jianjun, LIU Jing, CHEN Xiaoping, JIANG Yinong, XIE Liangdi, XIE Jianhong, XUE Hao, ZHANG Haifeng, CHEN Xin, JIA Nan, XU Jianzhong, XU Tingyan, CHENG Wenli. Chinese experts consensus on the use of α-blockers in antihypertensive therapy[J]. Chinese Journal of Hypertension, 2022, 30(5): 409-416. DOI: 10.16439/j.issn.1673-7245.2022.05.003
shu

Chinese experts consensus on the use of α-blockers in antihypertensive therapy

    Graphical Abstract
    • Abstract
  • α-blocker is a classic antihypertensive drug class and indispensable in the management of hypertension. This Chinese experts consensus document is the first that summarizes evidence and provides recommendations on the efficacy and safety of α-blockers in the treatment of refractory hypertension, hypertension with comorbid benign prostatic hyperplasia, dyslipidemia and hyperglycemia, and chronic kidney disease, hypertensive emergency, pheochromocytoma and primary aldosteronism under screening. It also attempts to provide guidance for the optimized use of α-blockers in the management of hypertension.
    • FullText(HTML)
  • loading
    • References (50)
    • Related Articles

Catalog

    Turn off MathJax
    Article Contents

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return